TSLA
Tesla
-- 248.710 NVDA
NVIDIA
-- 117.700 PLTR
Palantir
-- 90.960 AAPL
Apple
-- 218.270 MU
Micron Technology
-- 94.720 
NEWS
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
Omega Therapeutics (Nasdaq: OMGA) has published preclinical data for OTX-2002, their epigenomic controller targeting the MYC gene in hepatocellular carcinoma (HCC), in Nature Communications. The study demonstrates OTX-2002's ability to downregulate MYC expression and inhibit tumor growth in HCC models, both as a monotherapy and in combination with standard treatments.
Key findings include:
Rapid reduction in MYC mRNA and protein levels
Decreased viability of HCC cell lines
Dose-dependent tumor size reduction
Synergistic effects with other cancer therapies
Beneficial impact on the tumor microenvironment
OTX-2002 is currently in a Phase 1/2 clinical trial (MYCHELANGELO™ I) for HCC and other MYC-associated solid tumors. The data supports the potential of Omega's OMEGA platform to develop programmable epigenomic mRNA medicines for various diseases.
Omega Therapeutics (Nasdaq: OMGA) has published preclinical data for OTX-2002, their epigenomic controller targeting the MYC gene in hepatocellular carcinoma (HCC), in Nature Communications. The study demonstrates OTX-2002's ability to downregulate MYC expression and inhibit tumor growth in HCC models, both as a monotherapy and in combination with standard treatments.
Key findings include:
Rapid reduction in MYC mRNA and protein levels
Decreased viability of HCC cell lines
Dose-dependent tumor size reduction
Synergistic effects with other cancer therapies
Beneficial impact on the tumor microenvironment
OTX-2002 is currently in a Phase 1/2 clinical trial (MYCHELANGELO™ I) for HCC and other MYC-associated solid tumors. The data supports the potential of Omega's OMEGA platform to develop programmable epigenomic mRNA medicines for various diseases.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment